CIT joins EUR 10 million R&D project funded by EU and European cosmetic industry
CIT is one of 14 industrial and academic partners in the project, which is coordinated by Inserm, the French National Institute for Health and Medical Research. The “ScreenTox” project will be funded as part of a research cluster with an overall budget of EUR 50 million. This cluster covers seven projects and represents a unique joint effort from the European Commission and the European Cosmetic Association (COLIPA).
In the development of products for use by humans, it is vital to identify compounds with toxic properties at an early stage of their development, in order to avoid spending time and resources on unsuitable and potentially unsafe candidate products. Human pluripotent stem cells offer an unparalleled opportunity to create a wide variety of human cell-based test systems because these cells may be expanded indefinitely and triggered to differentiate into any cell type. The “ScreenTox” project aims at making use of these two attributes in order to optimize current processes and develop novel methods to achieve functional differentiation of human-based target cells in vitro.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.